Wade Andrews

A Cooley team advised Horizon Therapeutics, a specialty biopharmaceutical company, on its agreement to be acquired by Amgen. The approximately $28 billion merger would represent the third-largest all-cash transaction in the pharmaceutical sector in history and the biggest healthcare deal of 2022.

Cooley is advising Turning Point Therapeutics, a leading precision oncology company, on its definitive agreement to be acquired by global biopharmaceutical company Bristol Myers Squibb. Lawyers Barbara Borden, Rowook Park, Charles Bair, Lindsey O’Crump, Vivian Tsai and Melissa Meza are leading the Cooley team advising Turning Point Therapeutics.

Cooley advised Reneo Pharmaceuticals on its $93.8 million initial public offering of 6,250,000 shares of common stock. Reneo Pharmaceuticals, whose securities now trade on the Nasdaq Global Market under the symbol RPHM, is a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. Partners Jason Kent and Kristin VanderPas led the Cooley team.

Cooley advised Equillium, Inc. on its $65.4 million initial public offering of 4,670,000 shares of common stock. The underwriters have a 30-day option to purchase an additional 700,500 shares. Partners Tom Coll and Karen Anderson led the Cooley team advising Equillium.

Jefferies, Leerink Partners and Stifel Nicolaus & Company acted as joint book-running managers for the offering.

Equillium is a biotechnology company leveraging immunobiology to develop products for severe autoimmune and inflammatory disorders with a high unmet medical need. The company’s shares now trade on the Nasdaq Global Market under the symbol “EQ.”

Cooley advised HTG Molecular Diagnostics on its initial public offering. HTG is a commercial stage company that develops and markets a novel technology platform to facilitate the routine use of complex molecular profiling. The company trades on the Nasdaq Global Market under the symbol "HTGM."